Stroke Patient Appeals Eli Lilly Win on Cialis Label Claims

A man who says Eli Lilly & Co. failed to adequately warn doctors about stroke risk associated with the erectile dysfunction drug Cialis plans to appeal his suit after a federal court granted summary judgment on design defect and loss of consortium claims to the pharmaceutical company.

The design defect claim was federally preempted to the extent that it was based on the drug’s formulation because Cialis is approved by the Food and Drug Administration and Eli Lilly is prohibited from changing the medication without prior FDA approval, the US District Court for the Western District of Washington said on ...